# Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

> **NCT06186037** · PHASE4 · RECRUITING · sponsor: **Saint Vincent's Hospital, Korea** · enrollment: 6356 (estimated)

## Conditions studied

- Coronary Artery Disease
- Dyslipidemias
- Primary Prevention

## Interventions

- **DRUG:** Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
- **DRUG:** Mono drug group of Rosuvastatin 20 mg

## Key facts

- **NCT ID:** NCT06186037
- **Lead sponsor:** Saint Vincent's Hospital, Korea
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 6356 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186037, "Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06186037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*